Valeant Pharmaceuticals Intl Inc. Q4 Earnings Review: Hold on Tight

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) beat fourth-quarter earnings estimates, but it missed on revenues.

| More on:
The Motley Fool

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An investment in Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is not for the faint of heart. The company’s fall from grace has been well documented, and after losing as much as 95% of its market value, it has been highly volatile. Over the past six months, its share price has returned 33%, but year to date, the stock has unperformed, losing approximately 13% of its value.

Options buyers have had a big impact on the trajectory of the company’s stock price, particularly around earnings. Over the past two years, Valeant’s share price has fluctuated by approximately 20% on average the day after earnings are released. After it announced third-quarter results in November, the stock jumped 17.1% the next day.

What can investors expect after yesterday’s fourth-quarter results? If history is any indication, look for the share price to see downward pressure. Options buyers have been placing their bets on a positive reaction to earnings. Unfortunately, despite a beat on earnings, the company posted another double-digit revenue loss amid increased competition for some of its major products. Its top brand Bausch + Lomb saw sales decline 3%, while Branded Rx lost 19% year over year (YOY). Non-GAAP earnings before interest, taxes, depreciation, and amortization (EBITDA) didn’t fare any better dropping 16% YOY.

Investors can be looking at another double-digit decline immediately post earnings. Bulls will see this as a buying opportunity. Valeant has surpassed expectations and to date, it has successfully executed on its debt-reduction plan. The company generates significant cash flows, and it is well positioned to meet debt obligations over the next few years. As evidence of its success, the company announced plans to redeem the remaining balance of its $71 million unsecured notes due 2020 by March 30 of this year.

Although the company has been successful in paying down its significant debt load, at some point, investors will look for a return to growth. Bulls have pointed to the company’s “Magnificent Seven” pipeline of products, but the company’s revenues continue its downward trend. Unfortunately, the company has guided for another mid-single-digit decline in revenues for fiscal 2018.

Investors shouldn’t fall into the price-to-earnings (P/E) valuation trap. A P/E ratio of approximately six may seem extremely cheap, but it can be very misleading. The company is still trading at 1.55 times book value, and its P/E-to-growth ratio (PEG) is negative. Likewise, its enterprise value to EBITDA of 9.63 also implies that the company is not currently undervalued. At this point, an investment in Valeant is mainly for investors with a high risk tolerance. Those with low risk tolerance should stay on the sidelines until the company can stem the tide of declining revenues.

Should you invest $1,000 in Bausch Health Companies right now?

Before you buy stock in Bausch Health Companies, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Bausch Health Companies wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $20,697.16!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 29 percentage points since 2013*.

See the Top Stocks * Returns as of 3/20/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Mat Litalien has no positions in any of the stocks mentioned in this article.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Investing

A plant grows from coins.
Energy Stocks

2 Discounted Dividend Stocks With Significant Growth Potential

If you’re in search of income and capital appreciation in the long run, here are two discounted Canadian dividend stocks…

Read more »

protect, safe, trust
Dividend Stocks

Where I’d Allocate $20,000 in 2 Safer High-Yield Dividend Stocks for Retirement Needs

Here are two safer, high-yield dividend stocks I'm looking at for my retirement needs.

Read more »

Senior uses a laptop computer
Energy Stocks

Here’s How Investors Can Turn $15,000 in a TFSA Into $235,000

Energy stocks aren't created equal, and this one might be one of the best of the batch.

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Dividend Stocks

3 Reasons I’m Considering Enbridge Stock for a $5,000 Investment This April

I'm considering Enbridge stock to provide some defensive appeal and a juicy dividend to my long-term portfolio.

Read more »

monthly desk calendar
Dividend Stocks

A 9.2% Dividend Stock Paying Cash Every Single Month

With one of the highest dividends out there, this dividend stock deserves attention in your portfolio.

Read more »

Happy golf player walks the course
Dividend Stocks

Build a Powerful Passive Income Portfolio With Just $20,000

If you are worried that the bear market could reduce your savings, these stocks can build a powerful passive income…

Read more »

Hand Protecting Senior Couple
Dividend Stocks

How I’d Use My $7,000 TFSA Contribution to Start Retirement Planning

These TSX stocks have solid fundamentals and are well-positioned to deliver significant tax-free total returns over time.

Read more »

Safety helmets and gloves hang from a rack on a mining site.
Tech Stocks

Where I’d Invest $300 in the TSX Today

A TSX stock with a leading-edge safety technology is a screaming buy today for its high-growth potential.

Read more »